Our technology involves the introduction of an mRNA endoribonuclease or interferase in E. coli cells to disrupt the endogenous protein production, however, the cells retain full metabolic activity for RNA and protein synthesis. Therefore, when the mRNA for a protein of interest is engineered to be devoid of the mRNA endoribonuclease recognizing sequence without altering the amino acid sequence of the protein, the cells start to produce any single protein of your choice.

With the evolution of our technology, we are now capable to produce any proteins with the SPP system. With the technology, protein yields can be kept unaffected even when the culture is condensed up to 40-fold, and this reduces the cost of protein production by up to 97.5%. The technology provides isotope-labeled proteins at a very high signal-to-noise ratio. More than 90% of the isotope can be incorporated into the target protein in the SPP system. Furthermore, a refinement of our technology has eliminated lengthy purification steps in the production of membrane proteins suitable for structural studies.